112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience

Background

Historical data has demonstrated a synergistic anti-tumor response with the combination of immunotherapy, chemotherapy, and anlotinib for extensive-stage small-cell lung cancer (ES-SCLC). However, real-world evidence supporting this combination regimen is lacking. Therefore, we initiated a multicenter real-world study to evaluate the efficacy and safety of serplulimab (an anti-PD-1 mAb) combined with chemotherapy plus anlotinib for ES-SCLC patients.

Methods

Patients initially diagnosed with ES-SCLC who received serplulimab combined with chemotherapy and anlotinib between October 2020 and June 2024 were eligible for this study. The primary endpoint was overall survival (OS). The secondary endpoints were progress-free survival (PFS) and adverse events (AEs). Subgroup analyses were performed based on the different treatment lines.

Results

A total of 40 patients who received serplulimab combined with chemotherapy and anlotinib with a median age of 63 (range: 50-83) years were included in three centers. The main features included males (77.5%), smokers (67.5%), ECOG score of 1 (57.5%), and stage Ⅳ disease (87.5%). There were 28 patients received serplulimab as the first-line, 9 as the second-line, and 3 as the third-line. Anlotinib was administered to 5 patients in first-line, 13 in second-line, and 22 in third-line therapy. The median follow-up duration was 21.5 months (range: 5.2-46.7). The median OS from the initial diagnosis of all patients was 21.8 months (95%CI 15.6-NR). There was no significant difference in median OS between different anlotinib treatment lines (14.2 vs. NR vs. 21.8 months, P=0.737). The median PFS was numerically higher in patients receiving first-line combination therapy than those not treated with first-line anlotinib in combination (9.2 vs. 6.6 months, P=0.354). Any grade AEs occurred in 30 (75.0%) patients, with anemia being the most common (17, 42.5%). Grade ≥3 AEs were reported in 6 (15.0%) patients.

Conclusions

Our study revealed that serplulimab combined with chemotherapy and anlotinib as a front-line treatment regimen might benefit survival and is well-tolerated for ES-SCLC patients.

Legal entity responsible for the study

Jun Wang.

Funding

Clinical Research Capacity Building and Human Research Participants Protection Practice Platform (CCHRPP).

Disclosure

All authors have declared no conflicts of interest.